Evidence map›Paper›PMID 42094592›Full record

ArticleTheranostics2026

A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis.

Dingyu Wu, Lei Duan, Di Tan, Xinyi Hua, Anping Liang, Ruiping Huai, Shanshan Qi, Zhixian Shang, Shijie Jia, Hui Qi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dingyu WuKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Lei DuanSchool of Clinical Medicine, Dali University, Dali 671000, Yunnan, China.
Di TanSchool of Pharmacy, Dali University, Dali 671000, Yunnan, China.
Xinyi HuaKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Anping LiangKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Ruiping HuaiKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Shanshan QiKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Zhixian ShangKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Shijie JiaKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Hui QiKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Xinrong LiuKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Jieling ZhaoKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Yuhong JiangKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Rui TanKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.
Canquan MaoKey Laboratory of Advanced Materials Technology of the Ministry of Education, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver fibrosis is not only a major cause of cirrhosis but also an important risk factor for hepatocellular carcinoma (HCC). Currently, few drugs can effectively reverse established liver fibrosis. FOXM1, a transcription factor aberrantly activated in chronic liver disease, has been implicated in fibrosis-associated hepatocarcinogenesis. Nevertheless, effective pharmacological strategies for targeting FOXM1 are still lacking. Methods: We developed peptide-based proteolysis-targeting chimeras (PROTACs) by conjugating the FOXM1-binding peptide P49 with different E3 ligase ligands. Among them, P49-PROTAC Results: Mechanistically, P49-PROTAC Conclusions: The FOXM1-ADAMTS12 axis may represent an important molecular link between liver fibrosis and hepatocarcinogenesis. Targeting FOXM1 with peptide-based PROTACs may provide a promising therapeutic strategy to attenuate liver fibrosis and suppress HCC development.

Indexed as

Carcinoma, HepatocellularForkhead Box Protein M1Liver CirrhosisLiver NeoplasmsPeptidesAnimalsApoptosisCarcinogenesisCell Line, TumorCell ProliferationDisease Models, AnimalHumansMaleMiceProteolysisProteolysis Targeting ChimeraForkhead Box Protein M1FOXM1 protein, humanPeptidesProteolysis Targeting Chimeraa disintegrin and metalloproteinase with thrombospondin motif 12 (ADAMTS12)Forkhead box M1 (FOXM1)hepatocellular carcinomaliver fibrosisproteolysis-targeting chimera (PROTAC)

Identifiers

PMID42094592
PMCPMC13142673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.